An analyst issued the equivalent of a warning on Tandem Diabetes Care (NASDAQ: TNDM) stock on the second trading day of the ...

Analyst Jeff Johnson from Robert W. Baird reiterated a Hold rating on Tandem Diabetes Care (TNDM – Research Report) and increased the ...

RBC Capital Markets initiates coverage on Tandem Diabetes Care (TNDM) with an Outperform rating and $65 price target, citing ...

GAMMA Investing LLC increased its position in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM – Free Report) by 17.0% ...

Tandem Diabetes Care Inc (TNDM) reports a robust 12% sales growth in Q2 2024, driven by successful product launches and ...

Tandem Diabetes Care (NASDAQ: TNDM) had some encouraging news to report on the regulatory front Thursday, and after it hit the headlines investors piled into the stock. At the end of the day the ...

Insider trading activity involves company insiders, such as executives, directors, and employees, engaging in transactions of their own company's stock. Insiders' buy and sell transactions provide ...

Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that ...

周五，高盛开始对专门从事胰岛素泵的医疗设备公司Tandem Diabetes Care (NASDAQ:TNDM)股票进行评级，给予中性评级，目标价为46.00美元。这项评级始于对该公司在糖尿病治疗市场前景的分析。 该公司的中性立场基于几个平衡公司前景的因素。一方面，对1型糖尿病患者中胰岛素泵使用率的看法是积极的，预计将会增长。Tandem Diabetes还有望从新产品周期中受益，这可能有助于其 ...

The prognosticator behind that piece of bad news was Citigroup's Joanne Wuensch, who issued one of her bank's 90-day catalyst watches on Tandem stock before the market open. Wuensch wrote in her ...

In its press release trumpeting the EU's move, Tandem quoted its chief medical officer Jordan Pinsker as saying, "Ultra-rapid-acting insulin is a popular choice for people living with diabetes due ...